Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 2 | 2023 | 188 | 1.290 |
Why?
|
| Models, Biological | 4 | 2013 | 711 | 1.070 |
Why?
|
| Buprenorphine | 1 | 2023 | 51 | 0.800 |
Why?
|
| Melanoma | 1 | 2023 | 109 | 0.740 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 175 | 0.700 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 225 | 0.630 |
Why?
|
| Proportional Hazards Models | 4 | 2023 | 512 | 0.550 |
Why?
|
| HIV Infections | 5 | 2022 | 2535 | 0.520 |
Why?
|
| Humans | 25 | 2025 | 42163 | 0.410 |
Why?
|
| Phytoplankton | 1 | 2013 | 5 | 0.410 |
Why?
|
| Anti-HIV Agents | 3 | 2021 | 475 | 0.370 |
Why?
|
| Particulate Matter | 2 | 2025 | 80 | 0.370 |
Why?
|
| Education, Medical | 2 | 2023 | 117 | 0.360 |
Why?
|
| Air Pollutants | 2 | 2025 | 127 | 0.350 |
Why?
|
| United States | 6 | 2023 | 5072 | 0.350 |
Why?
|
| Adult Stem Cells | 1 | 2010 | 12 | 0.340 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 245 | 0.340 |
Why?
|
| Embryonic Stem Cells | 1 | 2010 | 55 | 0.330 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 350 | 0.320 |
Why?
|
| SEER Program | 2 | 2023 | 157 | 0.300 |
Why?
|
| Students, Medical | 2 | 2021 | 153 | 0.280 |
Why?
|
| Tennessee | 3 | 2025 | 88 | 0.280 |
Why?
|
| Multiple Myeloma | 1 | 2007 | 45 | 0.270 |
Why?
|
| Glioma | 1 | 2007 | 92 | 0.260 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 129 | 0.250 |
Why?
|
| Poliomyelitis | 1 | 2005 | 7 | 0.230 |
Why?
|
| Environmental Exposure | 2 | 2025 | 247 | 0.230 |
Why?
|
| Spheroids, Cellular | 1 | 2005 | 37 | 0.230 |
Why?
|
| Neoplasms | 2 | 2013 | 1341 | 0.230 |
Why?
|
| Mathematical Concepts | 2 | 2013 | 9 | 0.200 |
Why?
|
| Computer Simulation | 2 | 2021 | 404 | 0.200 |
Why?
|
| Systems Biology | 2 | 2013 | 26 | 0.200 |
Why?
|
| Population Dynamics | 2 | 2013 | 47 | 0.200 |
Why?
|
| Female | 12 | 2025 | 24018 | 0.200 |
Why?
|
| Nutrition Therapy | 1 | 2022 | 9 | 0.200 |
Why?
|
| Naloxone | 1 | 2023 | 56 | 0.200 |
Why?
|
| Models, Statistical | 2 | 2014 | 190 | 0.190 |
Why?
|
| Papillomavirus Vaccines | 1 | 2025 | 168 | 0.190 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 729 | 0.190 |
Why?
|
| Skin | 1 | 2023 | 185 | 0.180 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 1679 | 0.180 |
Why?
|
| Gastric Emptying | 1 | 2021 | 14 | 0.170 |
Why?
|
| Cell Proliferation | 4 | 2013 | 1420 | 0.170 |
Why?
|
| Papillomavirus Infections | 1 | 2025 | 363 | 0.170 |
Why?
|
| Atmospheric Pressure | 1 | 2020 | 11 | 0.170 |
Why?
|
| Primary Health Care | 1 | 2023 | 362 | 0.160 |
Why?
|
| Pressure | 1 | 2020 | 49 | 0.160 |
Why?
|
| Students, Dental | 1 | 2019 | 6 | 0.160 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 680 | 0.160 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 44 | 0.150 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2021 | 126 | 0.150 |
Why?
|
| Air Pollution | 1 | 2020 | 87 | 0.150 |
Why?
|
| Treatment Outcome | 1 | 2023 | 1586 | 0.150 |
Why?
|
| Benzo(a)pyrene | 1 | 2020 | 128 | 0.150 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 173 | 0.150 |
Why?
|
| Medication Adherence | 1 | 2021 | 177 | 0.150 |
Why?
|
| Retrospective Studies | 2 | 2023 | 2485 | 0.150 |
Why?
|
| Students, Nursing | 1 | 2019 | 37 | 0.150 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 279 | 0.150 |
Why?
|
| Prejudice | 1 | 2019 | 116 | 0.150 |
Why?
|
| Physicians | 1 | 2021 | 180 | 0.150 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2019 | 128 | 0.150 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 146 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 223 | 0.140 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 222 | 0.130 |
Why?
|
| Antioxidants | 1 | 2021 | 439 | 0.130 |
Why?
|
| Liver | 1 | 2020 | 503 | 0.130 |
Why?
|
| Saliva | 1 | 2017 | 115 | 0.130 |
Why?
|
| Male | 7 | 2025 | 22779 | 0.120 |
Why?
|
| Appalachian Region | 1 | 2014 | 5 | 0.110 |
Why?
|
| Southeastern United States | 1 | 2014 | 58 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 744 | 0.110 |
Why?
|
| History, 21st Century | 1 | 2014 | 85 | 0.110 |
Why?
|
| Logistic Models | 2 | 2017 | 1001 | 0.110 |
Why?
|
| History, 20th Century | 1 | 2014 | 124 | 0.110 |
Why?
|
| Algorithms | 2 | 2014 | 508 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 358 | 0.100 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 35 | 0.100 |
Why?
|
| Risk Factors | 4 | 2020 | 3942 | 0.100 |
Why?
|
| Biomass | 1 | 2013 | 66 | 0.100 |
Why?
|
| Mortality | 1 | 2014 | 174 | 0.100 |
Why?
|
| Texas | 1 | 2014 | 428 | 0.100 |
Why?
|
| Light | 1 | 2013 | 182 | 0.090 |
Why?
|
| RNA Interference | 1 | 2013 | 246 | 0.090 |
Why?
|
| Temperature | 1 | 2013 | 314 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2012 | 362 | 0.090 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 638 | 0.090 |
Why?
|
| Receptor, erbB-2 | 1 | 2012 | 149 | 0.090 |
Why?
|
| Iodoacetates | 1 | 2010 | 2 | 0.090 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2010 | 15 | 0.080 |
Why?
|
| Carcinoma, Ehrlich Tumor | 1 | 2010 | 18 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 174 | 0.080 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2010 | 72 | 0.080 |
Why?
|
| Prognosis | 1 | 2012 | 850 | 0.080 |
Why?
|
| Schools, Medical | 2 | 2023 | 208 | 0.080 |
Why?
|
| Animals | 5 | 2025 | 16695 | 0.080 |
Why?
|
| Viral Load | 2 | 2021 | 344 | 0.070 |
Why?
|
| Adult | 4 | 2025 | 13458 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 1554 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 933 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2021 | 733 | 0.060 |
Why?
|
| Middle Aged | 4 | 2025 | 11819 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 1 | 2005 | 506 | 0.050 |
Why?
|
| Vaccination | 1 | 2025 | 332 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 61 | 0.050 |
Why?
|
| Health Status Disparities | 2 | 2020 | 705 | 0.050 |
Why?
|
| Rural Population | 1 | 2025 | 352 | 0.050 |
Why?
|
| Young Adult | 2 | 2025 | 4936 | 0.050 |
Why?
|
| Adolescent | 2 | 2025 | 5950 | 0.040 |
Why?
|
| Pyloric Antrum | 1 | 2021 | 6 | 0.040 |
Why?
|
| Educational Status | 1 | 2023 | 335 | 0.040 |
Why?
|
| Self Care | 1 | 2022 | 173 | 0.040 |
Why?
|
| Community Health Services | 1 | 2023 | 207 | 0.040 |
Why?
|
| Acrolein | 1 | 2021 | 17 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3077 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2021 | 57 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 386 | 0.040 |
Why?
|
| Porosity | 1 | 2020 | 42 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 2021 | 89 | 0.040 |
Why?
|
| Bisexuality | 1 | 2023 | 210 | 0.040 |
Why?
|
| Weight Gain | 1 | 2021 | 138 | 0.040 |
Why?
|
| Community Health Centers | 1 | 2020 | 56 | 0.040 |
Why?
|
| Fluorescence | 1 | 2020 | 113 | 0.040 |
Why?
|
| Stereoisomerism | 1 | 2020 | 166 | 0.040 |
Why?
|
| Solvents | 1 | 2020 | 109 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2021 | 89 | 0.040 |
Why?
|
| Ambulatory Care Facilities | 1 | 2019 | 65 | 0.040 |
Why?
|
| Curcumin | 1 | 2021 | 115 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2019 | 138 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2021 | 381 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2019 | 189 | 0.030 |
Why?
|
| Gene Expression | 1 | 2021 | 692 | 0.030 |
Why?
|
| Water | 1 | 2020 | 314 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2021 | 1010 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2017 | 456 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2020 | 1729 | 0.030 |
Why?
|
| Mice | 2 | 2021 | 6490 | 0.030 |
Why?
|
| Homosexuality, Male | 1 | 2021 | 483 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2021 | 990 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2021 | 2111 | 0.020 |
Why?
|
| Refractive Errors | 1 | 2010 | 30 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2010 | 230 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 661 | 0.020 |
Why?
|
| Aged | 1 | 2019 | 7982 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2598 | 0.010 |
Why?
|